Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05279651

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

This study is a multicentre, randomized controlled trial of ivabradine versus placebo.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w Bydgoszczy, Bydgoszcz, Poland

Loading trial locations.

About this study

The PREVENT-MINS study is a 2,500 patient multicentre, superiority randomized controlled trial of ivabradine versus placebo. The primary objective of the trial is to determine the impact of ivabradine versus placebo on the risk of MINS in patients with or at risk of atherosclerotic disease who are followed for 30 days after noncardiac surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Undergoing noncardiac surgery
  • ≥45 years of age
  • Expected to require at least an overnight hospital admission after surgery
  • Provide written informed consent to participate in the PREVENT-MINS Trial, AND
  • Fulfill ≥1 of the following 5 criteria (A-E):

A. History of coronary artery disease B. History of peripheral arterial disease C. History of stroke D. Undergoing major vascular surgery, OR

E. Any 3 of 9 risk criteria:

i. Undergoing major surgery ii. History of congestive heart failure iii. History of a transient ischaemic attack iv. Diabetes and currently taking an oral hypoglycemic agent or insulin v. Age ≥70 years vi. History of hypertension vii. Serum creatinine >175 µmol/L (>2.0 mg/dl) viii. History of smoking within 2 years of surgery ix. Undergoing emergent/urgent surgery

Exclusion criteria

  • Conduction abnormalities:

A. Non-sinus rhythm on ECG B. Sinoatrial or AV (2nd and 3d degree) blocks C. Sick sinus syndrome D. Long QT syndrome E. Pacemaker dependent

  • Transplanted heart (or on waiting list)
  • Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil
  • Resting heart rate <65 beats per minute on the day of surgery
  • Systolic blood pressure <90 mmHg on the day of surgery
  • Acute decompensated heart failure, cardiogenic shock, acute myocarditis
  • Acute coronary syndrome within 2 months before surgery;
  • Stroke or transient cerebral ischaemia within 1 month before surgery
  • Known severe liver or kidney disease (MDRD creatinine clearance <15 mL/min)
  • Inability to tolerate oral intake
  • Recent use of ivabradine (<1 month)
  • Known allergy or hypersensitivity to ivabradine
  • Low-risk surgical procedure based on individual physician's judgment
  • Investigator considers the patient unreliable regarding requirement for study compliance
  • Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding
  • Previously enrolled in the PREVENT-MINS study

Treatment and study plan

Ivabradine

Drug

Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.

Placebo

Drug

Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.

Primary outcomes

  1. MINS

    Time frame: 30 days after randomization

    Number of patients who experience myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery.

Secondary outcomes

  1. A composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest

    Time frame: 30 days after randomization

    Number of patients who have at least one of the following: vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest

  2. MINS not fulfilling the 4th universal definition of myocardial infarction

    Time frame: 30 days after randomization

    Number of patients who experience MINS not fulfilling the 4th universal definition of myocardial infarction

  3. Myocardial infarction

    Time frame: 30 days after randomization

    Number of patients who experience a myocardial infarction

  4. Vascular death

    Time frame: 30 days after randomization

    Number of patients who die of vascular cause

  5. Stroke

    Time frame: 30 days after randomization

    Number of patients who experience a stroke

  6. All-cause mortality

    Time frame: 30 days after randomization

    Number of patients who die of any cause

  7. Days alive and at home

    Time frame: 30 days after randomization

    Average number of days when a patient is alive and out of hospital within 30 days after randomization

  8. Health-related quality of life

    Time frame: 30 days after randomization

    Average health-related quality of life (based on EuroQol 5 Dimension, five-level version [EQ-5D])

  9. Clinically important atrial fibrillation

    Time frame: 30 days after randomization

    Number of patients who experience clinically important atrial fibrillation

  10. Clinically significant bradycardia

    Time frame: 30 days after randomization

    Number of patients who experience clinically significant bradycardia

  11. Clinically significant hypotension

    Time frame: 30 days after randomization

    Number of patients who experience clinically significant hypotension

  12. Phosphenes

    Time frame: 30 days after randomization

    Number of patients who experience phosphenes

  13. Cancellation or postponement of surgery due to concerns about patient's heart rate

    Time frame: 30 days after randomization

    Number of surgeries cancelled or postponed due to heart rate concerns

  14. Peak troponin concentration

    Time frame: 30 days after randomization

    Peak troponin concentration during the index hospitalization

  15. Area under the curve troponin

    Time frame: 30 days after randomization

    Area under the curve of troponin concentrations measured during the hospitalization

  16. Intraoperative mean arterial pressure

    Time frame: 30 days after randomization

    Intraoperative mean arterial pressure measured during the index surgery to calculate the average intraoperative mean arterial pressure

  17. Intraoperative heart rate

    Time frame: 30 days after randomization

    Intraoperative heart rate measured during the index surgery to calculate the average heart rate

Other outcomes

  1. Cardiac revascularization

    Time frame: 30 days after randomization

    Number of patients who undergo cardiac revascularization

  2. Re-hospitalization for vascular reasons

    Time frame: 30 days after randomization

    Number of patients re-hospitalized for vascular reasons

  3. Acute myocardial injury according to Fourth Universal Definition of Myocardial Infarction

    Time frame: 30 days after randomization

    Number of patients who experience an acute myocardial injury according to Fourth Universal Definition of Myocardial Infarction

  4. Non-fatal cardiac arrest

    Time frame: 30 days after randomization

    Number of patients who experience non-fatal cardiac arrest

  5. Acute congestive heart failure

    Time frame: 30 days after randomization

    Number of patients who experience acute congestive heart failure

  6. Any symptomatic or asymptomatic episode of deep vein thrombosis or pulmonary embolism

    Time frame: 30 days after randomization

    Number of patients who experience any (symptomatic or asymptomatic) episode of deep vein thrombosis or pulmonary embolism

  7. International Society on Thrombosis and Haemostasis (ISTH) major bleeding

    Time frame: 30 days after randomization

    Number of patients who experience major bleeding (as defined by ISTH)

  8. BIMS

    Time frame: 30 days after randomization

    Number of patients who experience bleeding independently associated with mortality after noncardiac surgery (BIMS)

  9. Infection/Sepsis

    Time frame: 30 days after randomization

    Number of patients who experience infection/sepsis

  10. Acute kidney injury fulfilling Kidney Disease Improving Global Outcomes (KDIGO) criteria

    Time frame: 30 days after randomization

    Number of patients who experience an acute kidney injury (fulfilling KDIGO criteria)

  11. Acute kidney injury requiring dialysis

    Time frame: 30 days after randomization

    Number of patients who experience an acute kidney injury requiring dialysis

  12. Amputation

    Time frame: 30 days after randomization

    Number of patients who undergo an amputation

  13. Days outside of intensive care unit

    Time frame: 30 days after randomization

    Average number of days alive outside of intensive care/cardiac care unit within 30 days after randomization

  14. Length of hospital stay

    Time frame: 30 days after randomization

    Average length of hospital stay

  15. Length of intensive care unit stay

    Time frame: 30 days after randomization

    Average length of intensive care unit stay

  16. Discharge destination from the hospital

    Time frame: 30 days after randomization

    Number of patients discharge to home/long-term care facility/other

  17. All-cause mortality

    Time frame: 1 year after randomization

    Number of patients who die of any cause

  18. Vascular death

    Time frame: 1 year after randomization

    Number of patients who die of vascular cause

  19. Myocardial infarction

    Time frame: 1 year after randomization

    Number of patients who experience a myocardial infarction

  20. Cardiac revascularization

    Time frame: 1 year after randomization

    Number of patients who undergo cardiac revascularization

  21. Non-fatal cardiac arrest

    Time frame: 1 year after randomization

    Number of patients who experience non-fatal cardiac arrest

  22. Stroke

    Time frame: 1 year after randomization

    Number of patients who experience a stroke

  23. Health-related quality of life

    Time frame: 1 year after randomization

    Average health-related quality of life (based on EuroQol 5 Dimension, five-level version [EQ-5D])

  24. Amputation

    Time frame: 1 year after randomization

    Number of patients who have an amputation

  25. Re-hospitalization for vascular reasons

    Time frame: 1 year after randomization

    Number of patients who experience a re-hospitalization for vascular reasons

Sponsors and collaborators

Lead sponsor

Jagiellonian University

Other

Collaborators

  • Population Health Research Institute
  • Vanderbilt University Medical Center

Registry information

Official study title

Ivabradine for PREVENTion of Myocardial Injury After Noncardiac Surgery

Acronym: PREVENT-MINS

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Mar 15, 2022
Registry last updated
Sep 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.